KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Aurinia Pharmaceuticals (AUPH) EPS (Weighted Average and Diluted) (2020 - 2025)

Aurinia Pharmaceuticals (AUPH) has disclosed EPS (Weighted Average and Diluted) for 6 consecutive years, with $0.23 as the latest value for Q3 2025.

  • For the quarter ending Q3 2025, EPS (Weighted Average and Diluted) rose 130.0% year-over-year to $0.23, compared with a TTM value of $0.56 through Sep 2025, up 473.33%, and an annual FY2024 reading of $0.04, up 107.41% over the prior year.
  • EPS (Weighted Average and Diluted) was $0.23 for Q3 2025 at Aurinia Pharmaceuticals, up from $0.16 in the prior quarter.
  • Across five years, EPS (Weighted Average and Diluted) topped out at $0.23 in Q3 2025 and bottomed at -$0.4 in Q1 2021.
  • Average EPS (Weighted Average and Diluted) over 5 years is -$0.11, with a median of -$0.09 recorded in 2023.
  • The sharpest move saw EPS (Weighted Average and Diluted) tumbled 73.91% in 2021, then surged 1500.0% in 2025.
  • Year by year, EPS (Weighted Average and Diluted) stood at -$0.25 in 2021, then rose by 28.0% to -$0.18 in 2022, then fell by 5.56% to -$0.19 in 2023, then soared by 105.26% to $0.01 in 2024, then soared by 2200.0% to $0.23 in 2025.
  • Business Quant data shows EPS (Weighted Average and Diluted) for AUPH at $0.23 in Q3 2025, $0.16 in Q2 2025, and $0.16 in Q1 2025.